In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 8, 2011, Pages 981-987

  Tarnberg M ^a   Ostholm Balkhed A ^a,b   Monstein, H J ^a,b   Hallgren A ^a,b   Hanberger, H ^a,b   Nilsson, L E ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE CTX M; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTIBUTEN; ERTAPENEM; IMIPENEM; MECILLINAM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN;

AMPLICON; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; DRUG DETERMINATION; EPSILOMETER TEST; ESCHERICHIA COLI; HETEROZYGOTE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; ESCHERICHIA COLI; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 80051546373     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1183-4     Document Type: Article

References (44)

1. R Alsterlund B Carlsson L Gezelius, et al. 2009 Multiresistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak Scand J Infect Dis 41 6-7 410 415 19396721 10.1080/00365540902896079 1:CAS:528:DC%2BD1MXhtVamu77M
2. H Fang F Ataker G Hedin, et al. 2008 Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006 J Clin Microbiol 46 2 707 712 18094139 10.1128/JCM.01943-07 1:CAS:528: DC%2BD1cXis1ehsL8%3D (Pubitemid 351231321)
3. A Kjerulf DS Hansen D Sandvang, et al. 2008 The prevalence of ESBL-producing E. coli and Klebsiella strains in the Copenhagen area of Denmark APMIS 116 2 118 124 18321362 10.1111/j.1600-0463.2008.00777.x 1:CAS:528:DC%2BD1cXksFSlt7s%3D (Pubitemid 351347590)
4. B Lytsy L Sandegren E Tano, et al. 2008 The first major extended-spectrum beta-lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant Klebsiella pneumoniae producing CTX-M-15 APMIS 116 4 302 308 18397465 10.1111/j.1600-0463.2008.00922.x 1:CAS:528:DC%2BD1cXmsV2mu7o%3D (Pubitemid 351499162)
5. U Naseer OB Natås BC Haldorsen, et al. 2007 Nosocomial outbreak of CTX-M-15-producing E. coli in Norway APMIS 115 2 120 126 17295678 10.1111/j.1600-0463.2007.apm-547.x 1:CAS:528:DC%2BD2sXjsFektb0%3D (Pubitemid 46208087)
6. SD Nyberg M Osterblad AJ Hakanen, et al. 2007 Detection and molecular genetics of extended-spectrum beta-lactamases among cefuroxime-resistant Escherichia coli and Klebsiella spp. isolates from Finland, 2002-2004 Scand J Infect Dis 39 5 417 424 17464864 10.1080/00365540601105731 1:CAS:528: DC%2BD2sXmslKrtrg%3D (Pubitemid 46705753)
7. Jacoby G, Bush K.OXA-type β-lactamases. Available online at: http://www.lahey.org/Studies/other.asp#table1. Last date accessed 9 August 2010
8. R Bonnet 2004 Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes Antimicrob Agents Chemother 48 1 1 14 14693512 10.1128/AAC.48.1.1-14.2004 1:CAS:528:DC%2BD2cXlsVKltQ%3D%3D (Pubitemid 38040170)
9. European Antimicrobial Resistance Surveillance System (EARSS) (2005) EARSS manual 2005. Available online at: http://www1.szu.cz/cem/earss/docs/Earss- manual-2005.pdf. Last date accessed 2 February 2011
10. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2008) Expert rules in antimicrobial susceptibility testing. Available online at: http://www.srga.org/eucastwt/EUCAST%20Expert%20rules%20final%20April- 20080407.pdf. Last date accessed 9 August 2010
11. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2008) Expert rules. Home page at: http://www.eucast.org/expert-rules/. Last date accessed 9 August 2010
12. M Melzer I Petersen 2007 Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli J Infect 55 3 254 259 17574678 10.1016/j.jinf.2007. 04.007 (Pubitemid 47244918)
13. MJ Schwaber Y Carmeli 2007 Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis J Antimicrob Chemother 60 5 913 920 17848376 10.1093/jac/dkm318 1:CAS:528:DC%2BD2sXht1ShtrfM (Pubitemid 47617735)
14. RJ Cordery CH Roberts SJ Cooper, et al. 2008 Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome J Hosp Infect 68 2 108 115 18063198 10.1016/j.jhin.2007.10.011 1:STN:280:DC%2BD1c7ltV2gug%3D%3D
15. C Gudiol L Calatayud C Garcia-Vidal, et al. 2010 Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome J Antimicrob Chemother 65 2 333 341 19959544 10.1093/jac/dkp411 1:CAS:528:DC%2BC3cXhtVSqt7k%3D
16. M Ortega F Marco A Soriano, et al. 2009 Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome J Antimicrob Chemother 63 3 568 574 19126669 10.1093/jac/dkn514 1:CAS:528: DC%2BD1MXitVSitrw%3D
17. J Rodríguez-Baño MD Navarro L Romero, et al. 2006 Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge Clin Infect Dis 43 11 1407 1414 17083012 10.1086/508877 (Pubitemid 44845640)
18. M Tumbarello M Sanguinetti E Montuori, et al. 2007 Predictors of mortality in patients with bloodstream infections caused by extended-spectrum- beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment Antimicrob Agents Chemother 51 6 1987 1994 17387156 10.1128/AAC.01509-06 1:CAS:528:DC%2BD2sXmtlKrsrY%3D (Pubitemid 46903084)
19. M Tumbarello M Sali EM Trecarichi, et al. 2008 Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy Antimicrob Agents Chemother 52 9 3244 3252 18591273 10.1128/AAC.00063-08 1:CAS:528:DC%2BD1cXhtF2gtrfJ
20. KH Song JH Jeon WB Park, et al. 2009 Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study BMC Infect Dis 9 41 19361340 10.1186/1471-2334-9-41
21. C Bin W Hui Z Renyuan, et al. 2006 Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli Diagn Microbiol Infect Dis 56 4 351 357 16934430 10.1016/j.diagmicrobio.2006.06.015 (Pubitemid 44854354)
22. PR Lagacé-Wiens KA Nichol LE Nicolle, et al. 2006 Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum- beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate J Antimicrob Chemother 57 6 1262 1263 16565157 10.1093/jac/dkl102 (Pubitemid 44644442)
23. LE Nicolle MR Mulvey 2007 Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam Scand J Infect Dis 39 8 748 749 17654359 10.1080/00365540701367801 1:CAS:528: DC%2BD2sXotV2ltbc%3D (Pubitemid 47180483)
24. J Rodríguez-Baño JC Alcalá JM Cisneros, et al. 2008 Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli Arch Intern Med 168 17 1897 1902 18809817 10.1001/archinte.168. 17.1897
25. ND Gupta RE Smith I Balakrishnan 2009 Clinical efficacy of temocillin J Antimicrob Chemother 64 2 431 433 19520716 10.1093/jac/dkp208 1:CAS:528:DC%2BD1MXosFSrtLo%3D
26. HJ Monstein M Tärnberg LE Nilsson 2009 Molecular identification of CTX-M and blaOXY/K1 beta-lactamase genes in Enterobacteriaceae by sequencing of universal M13-sequence tagged PCR-amplicons BMC Infect Dis 9 7 19161622 10.1186/1471-2334-9-7
27. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2010) Breakpoint tables for interpretation of MICs and zone diameters. Available online at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST- files/Disk-test-documents/EUCAST-breakpoints-v1.1.pdf. Last date accessed 9 August 2010
28. British Society for Antimicrobial Chemotherapy (BSAC) (2010) BSAC methods for antimicrobial susceptibility testing. Available online at: http://www.bsac.org.uk/Resources/BSAC/Version-9.1-March-2010-final.pdf. Last date accessed 2 February 2011
29. DM Livermore R Hope S Mushtaq 2008 Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers Clin Microbiol Infect 14 Suppl 1 189 193 18154546 10.1111/j.1469-0691.2007.01858.x 1:CAS:528:DC%2BD1cXhtlehsro%3D (Pubitemid 350269202)
30. H Rodriguez-Villalobos V Malaviolle J Frankard, et al. 2006 In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli J Antimicrob Chemother 57 4 771 774 16501056 10.1093/jac/dkl046 1:CAS:528:DC%2BD28Xis1Glu78%3D
31. S Tofteland B Haldorsen KH Dahl, et al. 2007 Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway J Clin Microbiol 45 1 199 205 17079502 10.1128/JCM.01319-06 1:CAS:528: DC%2BD2sXhsFyntrs%3D (Pubitemid 46106427)
32. CH Liao WH Sheng JT Wang, et al. 2006 In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan J Microbiol Immunol Infect 39 1 59 66 16440125 1:CAS:528:DC%2BD28XksFCktbk%3D
33. K Thomas MJ Weinbren M Warner, et al. 2006 Activity of mecillinam against ESBL producers in vitro J Antimicrob Chemother 57 2 367 368 16354745 10.1093/jac/dki451 1:CAS:528:DC%2BD28XovVGnsg%3D%3D (Pubitemid 43160188)
34. DM Livermore R Hope EJ Fagan, et al. 2006 Activity of temocillin against prevalent ESBL-and AmpC-producing Enterobacteriaceae from south-east England J Antimicrob Chemother 57 5 1012 1014 16531428 10.1093/jac/dkl043 1:CAS:528:DC%2BD28Xjtlams74%3D
35. A Sorlózano J Gutiérrez JM Romero, et al. 2007 Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli J Basic Microbiol 47 5 413 416 17910106 10.1002/jobm.200710318 (Pubitemid 350003894)
36. DJ Hoban SK Bouchillon BM Johnson, et al. 2005 In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004) Diagn Microbiol Infect Dis 52 3 215 227 16105567 10.1016/j.diagmicrobio.2005.06. 001 1:CAS:528:DC%2BD2MXos1ait7o%3D (Pubitemid 41133548)
37. J Oteo C Navarro E Cercenado, et al. 2006 Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions J Clin Microbiol 44 7 2359 2366 16825350 10.1128/JCM.00447-06 1:CAS:528:DC%2BD28Xot1aktr8%3D (Pubitemid 44092399)
38. V Prakash JS Lewis 2nd ML Herrera, et al. 2009 Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases Antimicrob Agents Chemother 53 3 1278 1280 19124661 10.1128/AAC.01519-08 1:CAS:528:DC%2BD1MXivF2ksb8%3D
39. R Colodner Z Samra N Keller, et al. 2007 First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel Diagn Microbiol Infect Dis 57 2 201 205 17258084 10.1016/j.diagmicrobio.2006.07.011 1:CAS:528: DC%2BD2sXpvV2htw%3D%3D (Pubitemid 46156978)
40. HS Sader A Hsiung TR Fritsche, et al. 2007 Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype Diagn Microbiol Infect Dis 57 3 341 344 17141461 10.1016/j.diagmicrobio.2006.08.016 1:CAS:528:DC%2BD2sXisVCgtLc%3D (Pubitemid 46330648)
41. PJ Gavin MT Suseno RB Jr Thomson, et al. 2006 Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species Antimicrob Agents Chemother 50 6 2244 2247 16723596 10.1128/AAC.00381-05 1:CAS:528:DC%2BD28XlsVOhsro%3D (Pubitemid 43807556)
42. LR Peterson 2008 Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam Clin Microbiol Infect 14 Suppl 1 181 184 18154544 10.1111/j.1469-0691.2007.01864.x 1:CAS:528:DC%2BD1cXhtlehsr4%3D (Pubitemid 350269200)
43. JR Hernández C Velasco L Romero, et al. 2006 Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain Int J Antimicrob Agents 28 5 457 459 17008066 10.1016/j.ijantimicag.2006.08.014 (Pubitemid 44636180)
44. A Kiremitci EC Dinleyici N Erben, et al. 2008 In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey Expert Opin Pharmacother 9 9 1441 1449 18518776 10.1517/14656566.9.9.1441 1:CAS:528:DC%2BD1cXms1Wlu74%3D (Pubitemid 352005908)